Expression of porcine fusion protein IRF7/3(5D) efficiently controls foot-and-mouth disease virus replication

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11140-11153

  Rami´rez Carvajal, Lisbeth ^b,c   Segundo, Fayna Di´az San ^a   Hickman, Danielle ^a   Long, Charles R ^c   Zhu, James ^a   Rodri´guez, Luis L ^a   de los Santos, Teresa ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; IRF7 IRF3 5D FUSION PROTEIN; IRF7 IRF3 FUSION PROTEIN; UNCLASSIFIED DRUG; B18R PROTEIN, VACCINIA VIRUS; HYBRID PROTEIN; INTERFERON; INTERFERON INDUCING AGENT; INTERFERON REGULATORY FACTOR 7; RECOMBINANT VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

ADULT; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CATTLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; FEMALE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENE; IN VITRO STUDY; IN VIVO STUDY; ISG54 GENE; MOUSE; MX1 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; OAS1 GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; SURVIVAL RATE; SWINE; UPREGULATION; VIRUS REPLICATION; VIRUS TITRATION; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; VACCINATION; VIROLOGY;

ADENOVIRIDAE; ANIMALS; CATTLE; CELL LINE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; INTERFERON INDUCERS; INTERFERON REGULATORY FACTOR-7; INTERFERON TYPE I; MICE; RECOMBINANT FUSION PROTEINS; SWINE; VACCINATION; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84906991021     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00372-14     Document Type: Article

References (70)

1. Grubman MJ, Baxt B. 2004. Foot-and-mouth disease. Clin. Microbiol. Rev. 17:465-493. http://dx.doi.org/10.1128/CMR.17.2.465-493.2004.
2. Rodriguez LL, Gay CG. 2011. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev. Vaccines 10:377-387. http://dx.doi.org/10.1586/erv.11.4.
3. Whitton JL, Cornell CT, Feuer R. 2005. Host and virus determinants of picornavirus pathogenesis and tropism. Nat. Rev. Microbiol. 3:765-776. http://dx.doi.org/10.1038/nrmicro1284.
4. Ehrenfeld E, Domingo E, Ross RP. 2010. The picornaviruses. ASM Press, Washington, DC.
5. Mason PW, Grubman MJ, Baxt B. 2003. Molecular basis of pathogenesis of FMDV. Virus Res. 91:9-32. http://dx.doi.org/10.1016/S0168-1702(02) 00257-5.
6. Rodriguez LL, Grubman MJ. 2009. Foot and mouth disease virus vaccines. Vaccine 5(Suppl 4):D90-D94. http://dx.doi.org/10.1016/j.vaccine.2009.08.039.
7. Ludi A, Rodriguez LL. 2013. Novel approaches to foot-and-mouth disease vaccine development. Dev. Biol. (Basel) 135:107-116. http://dx.doi.org/10.1159/000313913.
8. Dias CC, Moraes MP, Weiss M, Diaz-San Segundo F, Perez-Martin E, Salazar AM, de los Santos T, Grubman MJ. 2012. Novel antiviral therapeutics to control foot-and-mouth disease. J. Interferon Cytokine Res. 32:462-473. http://dx.doi.org/10.1089/jir.2012.0012.
9. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferonmediated signaling. Nat. Rev. Immunol. 5:375-386. http://dx.doi.org/10.1038/nri1604.
10. Sen GC, Sarkar SN. 2007. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr. Top. Microbiol. Immunol. 316:233-250.
11. Sin WX, Li P, Yeong JP, Chin KC. 2012. Activation and regulation of interferon-beta in immune responses. Immunol. Res. 53:25-40. http://dx.doi.org/10.1007/s12026-012-8293-7.
12. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737. http://dx.doi.org/10.1038/ni1087.
13. Bartlett NW, Slater L, Glanville N, Haas JJ, Caramori G, Casolari P, Clarke DL, Message SD, Aniscenko J, Kebadze T, Zhu J, Mallia P, Mizgerd JP, Belvisi M, Papi A, Kotenko SV, Johnston SL, Edwards MR. 2012. Defining critical roles for NF-kappaB p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol. Med. 4:1244-1260. http://dx.doi.org/10.1002/emmm.201201650.
14. Thanos D, Maniatis T. 1995. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83:1091-1100. http://dx.doi.org/10.1016/0092-8674(95)90136-1.
15. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777. http://dx.doi.org/10.1038/nature03464.
16. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907,http://dx.doi.org/10.1038/nature09907.
17. Grubman MJ, Moraes MP, Diaz-San Segundo F, Pena L, de los Santos T. 2008. Evading the host immune response: how foot-and-mouth disease virus has become an effective pathogen. FEMS Immunol. Med. Microbiol. 53:8-17. http://dx.doi.org/10.1111/j.1574-695X.2008.00409.x.
18. Nfon CK, Ferman GS, Toka FN, Gregg DA, Golde WT. 2008. Interferon-alpha production by swine dendritic cells is inhibited during acute infection with foot-and-mouth disease virus. Viral Immunol. 21:68-77. http://dx.doi.org/10.1089/vim.2007.0097.
19. de los Santos T, de Avila Botton S, Weiblen R, Grubman MJ. 2006. The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferonmRNAand blocks the host innate immune response. J. Virol. 80:1906-1914. http://dx.doi.org/10.1128/JVI.80.4.1906-1914.2006.
20. Rodriguez-Pulido M, Borrego B, Sobrino F, Saiz M. 2011. RNA structural domains in noncoding regions of the foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice. J. Virol. 85: 6492-6501. http://dx.doi.org/10.1128/JVI.00599-11.
21. Wang D, Fang L, Bi J, Chen Q, Cao L, Luo R, Chen H, Xiao S. 2011. Foot-and-mouth disease virus leader proteinase inhibits dsRNA-induced RANTES transcription in PK-15 cells. Virus Genes 42:388-393. http://dx.doi.org/10.1007/s11262-011-0590-z.
22. Wang D, Fang L, Luo R, Ye R, Fang Y, Xie L, Chen H, Xiao S. 2010. Foot-and-mouth disease virus leader proteinase inhibits dsRNA-induced type I interferon transcription by decreasing interferon regulatory factor 3/7 in protein levels. Biochem. Biophys. Res. Commun. 399:72-78. http://dx.doi.org/10.1016/j.bbrc.2010.07.044.
23. Wang D, Fang L, Li P, Sun L, Fan J, Zhang Q, Luo R, Liu X, Li K, Chen H, Chen Z, Xiao S. 2011. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase. J. Virol. 85:3758-3766. http://dx.doi.org/10.1128/JVI.02589-10.
24. Perez-Martin E, Weiss M, Diaz-San Segundo F, Pacheco JM, Arzt J, Grubman MJ, de los Santos T. 2012. Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J. Virol. 86:4477-4487. http://dx.doi.org/10.1128/JVI.06683-11.
25. Wu Q, Brum MC, Caron L, Koster M, Grubman MJ. 2003. Adenovirusmediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J. Interferon Cytokine Res. 23:359-368. http://dx.doi.org/10.1089/107999003322226014.
26. Chinsangaram J, Moraes MP, Koster M, Grubman MJ. 2003. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J. Virol. 77:1621-1625. http://dx.doi.org/10.1128/JVI.77.2.1621-1625.2003.
27. Diaz-San Segundo F, Moraes MP, de los Santos T, Dias CC, Grubman MJ. 2010. Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression. J. Virol. 84: 2063-2077. http://dx.doi.org/10.1128/JVI.01874-09.
28. Dias CC, Moraes MP, Segundo FD, de los Santos T, Grubman MJ. 2011. Porcine type I interferon rapidly protects swine against challenge with multiple serotypes of foot-and-mouth disease virus. J. Interferon Cytokine Res. 31:227-236. http://dx.doi.org/10.1089/jir.2010.0055.
29. Lin R, Genin P, Mamane Y, Hiscott J. 2000. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 20:6342-6353. http://dx.doi.org/10.1128/MCB.20.17.6342-6353.2000.
30. Bramson JL, Dayball K, Hall JR, Millar JB, Miller M, Wan YH, Lin R, Hiscott J. 2003. Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine 21:1363-1370. http://dx.doi.org/10.1016/S0264-410X(02)00694-1.
31. Graham FL, Prevec L. 1991. Manipulation of adenovirus vectors. Methods Mol. Biol. 7:109-128. http://dx.doi.org/10.1385/0-89603-178-0:109.
32. Rieder E, Bunch T, Brown F, Mason PW. 1993. Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J. Virol. 67:5139-5145.
33. Grubman MJ, Baxt B, Bachrach HL. 1979. Foot-and-mouth disease virion RNA: studies on the relation between the length of its 3=-poly(A) segment and infectivity. Virology 97:22-31. http://dx.doi.org/10.1016/0042-6822(79)90369-6.
34. Moraes MP, Mayr GA, Grubman MJ. 2001. pAd5-Blue: direct ligation system for engineering recombinant adenovirus constructs. Biotechniques 31:1050, 1052, 1054-1056.
35. Moraes MP, de los Santos T, Koster M, Turecek T, Wang H, Andreyev VG, Grubman MJ. 2007. Enhanced antiviral activity against foot-andmouth disease virus by a combination of type I and II porcine interferons. J. Virol. 81:7124-7135. http://dx.doi.org/10.1128/JVI.02775-06.
36. Cheng G, Chen W, Li Z, Yan W, Zhao X, Xie J, Liu M, Zhang H, Zhong Y, Zheng Z. 2006. Characterization of the porcine alpha interferon multigene family. Gene 382:28-38. http://dx.doi.org/10.1016/j.gene.2006.06.013.
37. Cheng G, Zhao X, Chen W, Yan W, Liu M, Chen J, Zheng Z. 2007. Detection of differential expression of porcine IFN-alpha subtypes by reverse transcription polymerase chain reaction. J. Interferon Cytokine Res. 27:579-587. http://dx.doi.org/10.1089/jir.2006.0126.
38. Sang Y, Rowland RR, Hesse RA, Blecha F. 2010. Differential expression and activity of the porcine type I interferon family. Physiol. Genomics 42:248-258. http://dx.doi.org/10.1152/physiolgenomics.00198.2009.
39. Sang Y, Rowland RR, Blecha F. 2010. Molecular characterization and antiviral analyses of porcine type III interferons J. Interferon Cytokine Res. 30:801-807. http://dx.doi.org/10.1089/jir.2010.0016.
40. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55:611-622. http://dx.doi.org/10.1373/clinchem.2008.112797.
41. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(_delta delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
42. Diaz-San Segundo F, Dias CC, Moraes MP, Weiss M, Perez-Martin E, Owens G, Custer M, Kamrud K, de los Santos T, Grubman MJ. 2013. Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus. J. Virol. 87:5447-5460. http://dx.doi.org/10.1128/JVI.03462-12.
43. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
44. U.S. Office of Science and Technology Policy. 1985. Laboratory animal welfare: U.S. Government principles for utilization and care of vertebrates animal used in testing, research and training, notice. Fed. Regist. 50: 20864-20865.
45. Salguero FJ, Sa´nchez-Marti´n MA, Di´az-San Segundo F, deAvila A, Sevilla N. 2005. Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 332:384-396. http://dx.doi.org/10.1016/j.virol.2004.11.005.
46. De Ioannes P, Escalante CR, Aggarwal AK. 2011. Structures of apo IRF-3 and IRF-7 DNA binding domains: effect of loop L1 on DNA binding. Nucleic Acids Res. 39:7300-7307. http://dx.doi.org/10.1093/nar/gkr325.
47. Heylbroeck C, Balachandran S, Servant MJ, DeLuca C, Barber GN, Lin R, Hiscott J. 2000. The IRF-3 transcription factor mediates Sendai virus induced apoptosis. J. Virol. 74:3781-3792. http://dx.doi.org/10.1128/JVI.74.8.3781-3792.2000.
48. Diaz-San Segundo F, Weiss M, Perez-Martin E, Koster MJ, Zhu J, Grubman MJ, de los Santos T. 2011. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology 413:283-292. http://dx.doi.org/10.1016/j.virol.2011.02.023.
49. Golde WT, Pacheco JM, Duque H, Doel T, Penfold B, Ferman GS, Gregg DR, Rodriguez LL. 2005. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23: 5775-5782. http://dx.doi.org/10.1016/j.vaccine.2005.07.043.
50. Pacheco JM, Brum MC, Moraes MP, Golde WT, Grubman MJ. 2005. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337:205-209. http://dx.doi.org/10.1016/j.virol.2005.04.014.
51. Mayr GA, Chinsangaram J, Grubman MJ. 1999. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263:496-506. http://dx.doi.org/10.1006/viro.1999.9940.
52. Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ. 2001. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19:2152-2162. http://dx.doi.org/10.1016/S0264-410X(00)00384-4.
53. Chinsangaram J, Koster M, Grubman MJ. 2001. Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. J. Virol. 75: 5498-5503. http://dx.doi.org/10.1128/JVI.75.12.5498-5503.2001.
54. Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 76:5532-5539. http://dx.doi.org/10.1128/JVI.76.11.5532-5539.2002.
55. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270: 15974-15978. http://dx.doi.org/10.1074/jbc.270.27.15974.
56. Symons JA, Alcami A, Smith GL. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560. http://dx.doi.org/10.1016/0092-8674(95)90076-4.
57. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. 2004. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J. Biol. Chem. 279:45194-45207. http://dx.doi.org/10.1074/jbc.M400726200.
58. Asensio VC, Maier J, Milner R, Boztug K, Kincaid C, Moulard M, Phillipson C, Lindsley K, Krucker T, Fox HS, Campbell IL. 2001. Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J. Virol. 75:7067-7077. http://dx.doi.org/10.1128/JVI.75.15.7067-7077.2001.
59. Marie´ I, Durbin JE, Levy DE. 1998. Differential viral induction of distinct interferon alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660-6669. http://dx.doi.org/10.1093/emboj/17.22.6660.
60. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N. 1998. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441:106-110. http://dx.doi.org/10.1016/S0014-5793(98)01514-2.
61. Bego MG, Mercier J, Cohen EA. 2012. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J. Virol. 86:3513-3527. http://dx.doi.org/10.1128/JVI.06971-11.
62. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84: 12646-12657. http://dx.doi.org/10.1128/JVI.01328-10.
63. Clarke JB, Spier RE. 1983. An investigation into causes of resistance of a cloned line of BHK cells to a strain of foot-and-mouth disease virus. Vet. Microbiol. 8:259-270. http://dx.doi.org/10.1016/0378-1135(83)90078-0.
64. Moutailler S, Roche B, Thiberge JM, Caro V, Rougeon F, Failloux AB. 2011. Host alternation is necessary to maintain the genome stability of Rift Valley fever virus. PLoS Negl. Trop. Dis. 5:e1156. http://dx.doi.org/10.1371/journal.pntd.0001156.
65. Amadori M, Volpe G, Defilippi P, Berneri C. 1997. Phenotypic features of BHK-21 cells used for production of foot-and-mouth disease vaccine. Biologicals 25:65-73. http://dx.doi.org/10.1006/biol.1996.0061.
66. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. 2007. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 179:3434-3442. http://dx.doi.org/10.4049/jimmunol.179.6.3434.
67. Iversen MB, Paludan SR. 2010. Mechanisms of type III interferon expression. J. Interferon Cytokine Res. 30:573-578. http://dx.doi.org/10.1089/jir.2010.0063.
68. Siegel R, Eskdale J, Gallagher G. 2011. Regulation of IFN-_1 promoter activity (IFN-_1/IL-29) in human airway epithelial cells. J. Immunol. 187: 5636-5644. http://dx.doi.org/10.4049/jimmunol.1003988.
69. Van Pesch V, Lanaya H, Renauld JC, Michiels T. 2004. Characterization of the murine alpha interferon gene family. J. Virol. 78:8219-8228. http://dx.doi.org/10.1128/JVI.78.15.8219-8228.2004.
70. Lefevre F, Guillomot M, D'Andrea S, Battegay S, La Bonnardiere C. 1998. Interferon-delta: the first member of a novel type I interferon family. Biochimie 80:779-788. http://dx.doi.org/10.1016/S0300-9084(99)80030-3.